Immune Shield — Complete Repair vs Specific Dysfunction

Practitioner clinical-education reference

Audience: Licensed practitioners using PeptidesPro
Companion patient guide: /guides/blend-immune-shield
Catalog kit: Immune Shield (IMSH15) — Thymosin Alpha-1 5 mg + Thymalin 5 mg + KPV 5 mg · SC
Status: Research / educational. Not a prescription protocol.

Core thesis

Immune Shield is the right core blend for T-cell restoration with a cytokine brake.

It is not a complete immune-system repair kit. Complete reconstitution needs terrain (barrier / innate) before thymic activation, and T-cell differentiation (Thymulin + zinc) after priming.

Do not put five immune peptides in one syringe on day one. Sequence the jobs.

What is in the vial vs what is adjacent

Peptide	In Immune Shield?	Job	Layer
Thymosin Alpha-1 (Tα1)	Yes	Matures/activates T-cells, dendritic cells, NK cells; Th1 / IL-2 / IFN-γ. Strongest clinical literature of the trio (thymalfasin / Zadaxin in 35+ countries for selected indications).	Adaptive activation
Thymalin	Yes	Bovine thymic polypeptide extract (mixture). Broad thymic priming, output, homeostasis. Not zinc-dependent.	Thymic soil / balance
KPV	Yes	α-MSH C-terminal tripeptide. NF-κB suppression (TNF-α, IL-6, IL-1β). Gut barrier / GALT calm.	Brake
Thymulin	No	Zinc-dependent nonapeptide. Differentiates thymocytes into CD4 / CD8 / Treg. Inactive without zinc.	T-cell education
LL-37	No	Human cathelicidin. Innate first responder, biofilms, dendritic / MHC-II presentation. Vitamin D–linked. TLR-active.	Innate + antigen presentation

Critical disambiguation

Thymalin ≠ Thymulin. Substituting one for the other is a protocol error.

Thymalin = extract / early priming / no zinc requirement
Thymulin = single 9-aa peptide / late differentiation / zinc required (picolinate or bisglycinate 25–50 mg/day; not oxide)

Complete immune repair (best combination)

Immune Shield covers activate + prime + regulate. Full repair adds terrain and differentiation.

Phase	Goal	Combination
1 — Reset	Calm fire, restore gut-immune schoolhouse, clear pathogens if present	KPV + BPC-157 ± LL-37 (only if chronic infection / biofilm / dysbiosis)
2 — Reboot	Restore T-cell command without a flare	Immune Shield (Tα1 + Thymalin + KPV). KPV may continue from Phase 1.
3 — Rebuild	Structure + subtype programming	Thymulin + zinc ± TB-4 / TB-500 (thymic architecture). Not in the Shield kit.
4 — Hold	Lock gains	Tα1 maintenance ± Thymulin. Optional Epitalon + Thymalin (Khavinson) for immune age.

Do not start Tα1 in an active cytokine storm or untreated barrier leak. KPV (and usually BPC-157) first.

Best combination by type of dysfunction

Dysfunction	Lead problem	Best combo	Avoid / delay
Immunosenescence / low T-cell output / frequent infections	Weak surveillance	Immune Shield, then Thymulin + zinc. Lean pair if little inflammation: Tα1 + Thymulin.	LL-37 unless infections are documented
Autoimmune (Hashimoto, RA, lupus, MS)	Over-active, poor tolerance	KPV ± BPC-157 first; Thymalin as balancer; Tα1 late and low after calm. Then Thymulin for Treg/tolerance.	Early Tα1 (flare risk). Delay LL-37 (TLR agonist) until mucosa is calm
Post-viral / long COVID / cytokine hangover	Exhausted T-cells + leftover fire	Tα1 + KPV or full Immune Shield	Thymulin before any Tα1/Thymalin priming
Chronic infection (Lyme, EBV, biofilm, recurrent sinus)	Innate + presentation failure	Phase 1: LL-37 + KPV ± BPC-157 → Phase 2: Tα1 + Thymalin	LL-37 as a default “forever” add-on
Antibody / B-cell failure (hypogammaglobulinemia)	Humoral factory	Full master sequence: KPV/BPC ± LL-37 → Tα1 → TB-4 + Thymulin	Shield alone — it does not rebuild class switching
Post-chemo / T-cell depletion	Need reconstitution	Short KPV/BPC reset → Shield → Thymulin + zinc. Caution TB-4 if malignancy risk (angiogenesis).	Unsupervised Tα1 in transplant patients
Gut-driven immune noise (IBD, leaky gut → flares)	GALT on fire	BPC-157 + KPV first. Add Tα1/Thymalin only after barrier improves.	Thymic peptides as the first move
Prevention / otherwise well	Modulation	Immune Shield or leaner Tα1 + KPV	Adding LL-37 and Thymulin “just in case”

Catalog ladder (immune family)

Goal	Start lean	Escalate
Immune reconstitution	Tα1 + Thymulin	Cytokine brake → Tα1 + KPV; full stack → Immune Shield
Post-viral, residual fire	Tα1 + KPV	Add Thymalin → Immune Shield
Complex / immune age + inflammation	Immune Shield	Then Thymulin + zinc; ± LL-37 only if infection

Related patient guides: /guides/blend-immune-shield · /guides/blend-takpv10 · /guides/blend-tath10

How to think about the two mention-only peptides

Thymulin — not a day-1 blend-mate. Last thymic move after Tα1/Thymalin have created precursors. Always with zinc. Without zinc it is biologically inactive.

LL-37 — not a T-cell peptide. Innate + “show the antigen.” Use when there is something to clear. In autoimmune, after KPV, not in the same opening week as Tα1.

Monitoring (educational)

Baseline and roughly weeks 8 / 16 / 24:

CBC with differential
CD4 / CD8
CRP / ESR ± IL-6
Immunoglobulins if humoral failure is in the story
Serum zinc before Thymulin

Protocol-engine alignment (PeptidesPro)

Immune Shield is the preferred Phase 2 stack for immune_deficiency.
Autoimmune: hold Tα1 until KPV/Thymalin have established balance; LL-37 delayed.
Thymulin is Phase 4 in all condition classes — it differentiates cells that Phase 2 activated.
See also: master-immune-restoration-protocol.md, thymic-reboot-protocol.md, thymalin.md, thymulin.md, kpv.md, ll-37.md.

Disclosures

Educational / professional discussion only. Not medical advice, diagnosis, or a prescription. Research and compounding status vary by jurisdiction. Multi-agent kits multiply variables — start with the fewest agents that cover the real layers.